Hollis Viray - Concepedia

Author

Hollis Viray

Beth Israel Deaconess Medical Center ORCID

Also Known As

H. Viray, Hollis Viray

Publications

453

Citations

H-Index

Concepts

All Affiliations

Beth Israel Deaconess Medical Center Harvard University Lahey Hospital and Medical Center Yale University Lahey Medical Center

About

Hollis Viray is an author at Beth Israel Deaconess Medical Center specializing in oncology, pathology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	57
2	Pathology	3	3	57
3	Cancer Therapeutics	2	2	37
4	Engineering	1	1	20
5	Pharmacology	1	1	24

Hollis Viray

Publications

415

Citations

H-Index

Page 1

	Year	Citations
A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells Hollis Viray, Kevin Li, Thomas A. Long, Archives of Pathology & Laboratory Medicine	2013	104
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors Pedro Eduardo Nascimento Silva Vasconcelos, Carol Gergis, Hollis Viray, JTO Clinical and Research Reports	2020	79
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? Kartik Sehgal, Andreas Varkaris, Hollis Viray, Journal for ImmunoTherapy of Cancer	2020	48
Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas Hollis Viray, W Bradley, Kurt A. Schalper, Archives of Pathology & Laboratory Medicine	2013	29
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Kartik Sehgal, Andrew J. Piper‐Vallillo, Hollis Viray, Precision Cancer Medicine	2020	24
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Kartik Sehgal, Andrew J. Piper‐Vallillo, Hollis Viray, Precision Cancer Medicine Distinct SubgroupMedicineCancer ManagementMetronomic TherapyPharmacology	2020	24
Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer Anastasios Dimou, Seema Agarwal, Valsamo Anagnostou, American Journal Of Pathology	2011	21
Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing Hollis Viray, Madeline Coulter, Kevin Li, Applied immunohistochemistry & molecular morphology EngineeringMutation TestingDigital PathologyDiagnosisPathology	2013	20
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice Hollis Viray, Andrew J. Piper‐Vallillo, Page Widick, Cancers	2024	16
Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership Andrew J. Piper-Valillo, Hollis Viray, Jill Feldman, Journal of Clinical Oncology	2024	14

Page 1